Sort   by:  
 Page size 
UnknownCarfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma.
Not available
S-EPMC5009511 | biostudies-literature
UnknownCarfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment.
Not available
S-EPMC5436074 | biostudies-literature
UnknownA phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma.
Not available
S-EPMC4737504 | biostudies-literature
UnknownCarfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study.
Not available
S-EPMC5412871 | biostudies-literature
UnknownImpact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study.
Not available
S-EPMC5220137 | biostudies-literature
Sort   by:  
 Page size